Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of claseprubart in generalized myasthenia gravis
NL-OMON59658Phase 2Completed
- Sponsor
- Dianthus Therapeutics
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of claseprubart in myasthenia gravis (MG) (3 arms), sponsored by Dianthus Therapeutics. Primary endpoint: Safety and tolerability of claseprubart up to Week 13. Started Dec 2024; status: completed.
02
Drugs
claseprubart
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON59658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59658.